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Abstract
Most infants with very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD)
identified by newborn screening (NBS) are asymptomatic at the time of diagnosis and
remain asymptomatic. If this outcome is due to prompt diagnosis and initiation of ther-
apy, or because of identification of individuals with biochemical abnormalities who will
never develop symptoms, is unclear. Therefore, a 10-year longitudinal national cohort
study of genetically confirmed VLCADD patients born before and after introduction of
NBS was conducted. Main outcome measures were clinical outcome parameters, acyl-
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CoA dehydrogenase very long chain gene analysis, VLCAD activity, and overall capac-
ity of long-chain fatty acid oxidation (LC-FAO flux) in lymphocytes and cultured skin
fibroblasts. Median VLCAD activity in lymphocytes of 54 patients, 21 diagnosed pre-
NBS and 33 by NBS was, respectively, 5.4% (95% confidence interval [CI]: 4.0-8.3)
and 12.6% (95% CI: 10.7-17.7; P < 0.001) of the reference mean. The median LC-
FAO flux was 33.2% (95% CI: 22.8-48.3) and 41% (95% CI: 40.8-68; P < 0.05) of the
control mean, respectively. Clinical characteristics in 23 pre-NBS and 37 NBS patients
revealed hypoglycemic events in 12 vs 2 patients, cardiomyopathy in 5 vs 4 patients
and myopathy in 14 vs 3 patients. All patients with LC-FAO flux <10% developed
symptoms. Of the patients with LC-FAO flux >10% 7 out of 12 diagnosed pre-NBS vs
none by NBS experienced hypoglycemic events. NBS has a clear beneficial effect on
the prevention of hypoglycemic events in patients with some residual enzyme activity,
but does not prevent hypoglycemia nor cardiac complications in patients with very low
residual enzyme activity. The effect of NBS on prevalence and prevention of
myopathy-related complications remains unclear.
KEYWORD S
cardiomyopathy, fatty acid oxidation, hypoglycemia, myopathy, newborn screening, very-long-chain
acyl-CoA dehydrogenase deficiency
1 | INTRODUCTION
Very-long-chain acyl-CoA dehydrogenase deficiency
(VLCADD) (OMIM 201475) is an autosomal recessive
inherited disorder of mitochondrial long-chain fatty acid oxi-
dation (LC-FAO), in which energy homeostasis is compro-
mised and long-chain (14-20 carbon atoms long) fatty acids
accumulate.1 Clinical symptoms arise, or are provoked, dur-
ing catabolic situations such as exercise, illness, or fasting.
In infancy, major symptoms include hypoketotic hypoglyce-
mia, rhabdomyolysis, cardiomyopathy, and arrhythmia, all
of which can be fatal. Exercise intolerance, myopathy, and
exercise-induced rhabdomyolysis often present at a later
age.2–6 There is a marked variability in clinical severity
among patients.
In the Netherlands, VLCADD has been included in the
newborn screening (NBS) panel since 2007. Screening is
performed by measuring the concentration of tetradecenoyl
carnitine (C14:1) and acetylcarnitine (C2) in dried blood
spots between 72 and 168 hours after birth. Since 2013, the
cutoff value (COV) of the C14:1/C2 ratio for referral of
newborns has been set at ≥0.023. Between 2007 and 2013,
screening was solely based on C14:1 levels
(COV ≥ 0.8 μmol/L), which failed to identify five patients
who were only diagnosed retrospectively upon reevaluation
of the blood spot results in 2010.7
NBS is widely regarded as a successful public health ini-
tiative that leads to improved treatment and disease out-
comes. With the addition of VLCADD to NBS, the number
of diagnosed patients rapidly increased. Most infants are
asymptomatic at time of diagnosis and remain asymptom-
atic.5 The question is whether this is due to prompt diagnosis
and start of therapy or because individuals with biochemical
abnormalities who will never develop symptoms are identi-
fied. Phenotype prediction based on molecular analysis is
challenging since various missense mutations or variants of
uncertain significance with unknown effects on protein level
and catalytic activity of the enzyme are observed in both
severe and milder phenotypes.8 Functional studies of lym-
phocytes and fibroblasts measuring residual LC-FAO rates
aid individualized therapeutic strategies but are only avail-
able in a few metabolic centers.9,10
Treatment of VLCADD is aimed at preventing catabo-
lism by avoidance of fasting.6,11 In addition, a long-chain
triglyceride (LCT)-restricted diet supplemented with
medium-chain triglycerides (MCT) is traditionally advised
to bypass long-chain fat oxidation for energy production.6,11
Recent studies support a more relaxed dietary regimen with-
out restrictions under healthy circumstances in patients with
a milder phenotype.8,9
The Dutch National Institute for Public Health and the
Environment has facilitated a nationwide program to moni-
tor clinical and biochemical features of all known VLCADD
patients in the Netherlands. This program includes all
VLCADD patients diagnosed by NBS (henceforth referred
to as NBS patients) as well as patients born before the intro-
duction of NBS (referred to as pre-NBS patients). The data
collected in this program offer a unique opportunity to
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evaluate the effect of a decade of NBS in the Netherlands on
the genetic and biochemical characteristics as well as clinical
outcomes of VLCADD patients.
2 | METHODS
2.1 | Study design and setting
1. Comparison of genetic and biochemical studies in genet-
ically confirmed VLCADD patients born before the
addition of VLCADD to NBS (pre-NBS) and patients
born in the 11 years after implementation of VLCADD
in NBS (January 2007-January 2018) (Figure 1A).
2. Longitudinal evaluation of outcome-related clinical char-
acteristics of the same cohort (March 2010-March 2018)
(Figure 1B).
The study was approved by the medical ethics committee
of the University Medical Center Utrecht (METC10-430/C;
METC15-582/C). Informed consent was obtained for all
patients participating in this study.
2.2 | Patients
Patients were identified by using the Dutch Diagnosis Regis-
tration Metabolic Diseases (DDRMD, www.ddrmd.nl) and
by contacting all Dutch metabolic centers. Date of birth was
available in all patients. Age at diagnosis was available in
19 out of 27 pre-NBS patients and all NBS patients.
2.3 | VLCAD activity
VLCAD activity measured in lymphocytes is currently stan-
dard practice once a patient is referred after a positive NBS
test for VLCADD. VLCAD activity in lymphocytes and
fibroblasts was measured using palmitoyl-CoA as substrate
as described previously12; the results are shown as a percent-
age of the reference mean and were valid at the time of anal-
ysis. Older patients were usually diagnosed based on
enzymatic testing of cultured skin fibroblasts, hence the
inclusion of both cell types in this study.
2.4 | Overall measurement of the
LC-FAO flux
The LC-FAO flux in fibroblasts was defined as the produc-
tion of radiolabeled H2O from [9,10-3H(N)]-oleic acid in
nanomoles of fatty acid oxidized per hour per milligram of
cellular protein as described previously.10,13,14 The LC-FAO
flux is expressed as a percentage of the mean activity of skin
fibroblasts of two healthy controls measured in the same
experiment. As previously described by Diekman et al10 LC-
FAO flux measured in fibroblasts correlates better to clinical
severity compared to enzyme activity, which is why this
assay was included in our study.
2.5 | Genotype
Mutation analysis of the acyl-CoA dehydrogenase very
long-chain gene (OMIM 609575) was performed by
sequence analysis of all exons and flanking intronic
sequences amplified by polymerase chain reaction from
FIGURE 1 Flowchart of VLCADD patients included. A, Genetic and biochemical characteristics study. B, Outcome-related clinical
characteristics study. LC-FAO flux, long-chain fatty acid oxidation flux; NBS, newborn screening; pre-NBS, before the addition of VLCADD to
NBS panel. VLCADD, very-long-chain acyl-CoA dehydrogenase deficiency
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genomic DNA isolated from either fibroblasts or blood from
the patients.
2.6 | Clinical evaluation
In the Dutch FAO Expertise Center, patients were seen by a
multidisciplinary team comprising metabolic specialists,
research dieticians, neurologists, physical therapists, and car-
diologists. During visits, patients received standardized
interviews about medical history, current complaints, daily
(sports) activities, and dietary habits.
Details on historical events were verified by collecting
patient records from their local hospital.
Hypoglycemia was defined as documented blood glucose
concentrations <45 mg/dL (<2.5 mmol/L).
Cardiomyopathy and/or arrhythmia was defined as
abnormal results on echocardiography (with left or right ven-
tricular wall thickness of at least one segment >2 SD, cor-
rected for age) and/or electrocardiographic abnormalities.
The definition of myopathy was based on the previously
reported clinical severity score for VLCADD10 (documented
plasma creatine kinase [CK] concentration ≥ 250 U/L [ref-
erence values 70-170 U/L] as well as at least two of the fol-
lowing symptoms: myoglobinuria, myalgia, exercise
intolerance, muscle weakness (Medical Research Council
[MRC] grade 4 or less), and/or frequent fatigue). Rhabdo-
myolysis was defined as a plasma CK concentration
≥1000 U/L.
Physical examination was performed in all patients as
well as validated motor development tests (Bayley Scales of
Infant and Toddler Development [third edition], Movement
Assessment Battery for Children [second edition], and
Bruininks-Oseretsky Test of Motor Proficiency [second edi-
tion] in children and adolescents;15–17). Scores ≤ − 2 SD
were considered abnormal.
2.7 | Statistical analysis
Statistical analyses were performed using SPSS Statistics
software version 23 (IBM Corp., Armonk, New York).
Average levels of enzyme activity and LC-FAO flux and
age of onset of clinical symptoms were compared between
groups using the Mann-Whitney U test. A Fisher's exact test
was used to compare categorical clinical data. All statistical
tests were two-sided with a P-value of ≤0.05 considered
significant.
2.8 | Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. The corresponding author had access to all data in
the study and had responsibility for the decision to submit
for publication. The study was approved by the medical
ethics committee of the University Medical Center Utrecht
(METC10-430/C; METC15-582/C). All procedures fol-
lowed were in accordance with the ethical standards of the
responsible committee on human experimentation (institu-
tional and national) and with the Helsinki Declaration of
1975, as revised in 2000. Informed consent was obtained
from all patients for being included in the study. Trial regis-
tration: Nederlands Trial Register, ID: NTR6582, http://
www.trialregister.nl/trialreg/admin/rctview.asp?TC=6582
3 | RESULTS
3.1 | Comparison of genetic and biochemical
studies in VLCADD patients diagnosed before
and after the introduction of NBS
3.1.1 | Patients
In the Netherlands, participation in the population NBS pro-
gram is ~99.5%.18 On 1 January 2018, a total of 64 geneti-
cally confirmed VLCADD patients were registered in the
DDRMD, 37 of whom were diagnosed by NBS (Figure 1).
Table S1 shows the characteristics of all patients. On
1 January 2018, four deaths in the pre-NBS (before 1 January
2007) as well as four deaths in the NBS group (since January
2007) had been reported. In the NBS group 1, VLCADD
deficient newborn passed away before NBS was performed
and was diagnosed by post-mortem testing. The overall
death rate was 15% in the pre-NBS group and 11% in the
NBS group (including this patient). These number can, how-
ever, not be compared as it is highly likely that in the pre-
NBS group deceased patients were not diagnosed, and there-
fore under-represented in the calculated death rate in the pre-
NBS group. Before the introduction of NBS on VLCADD
in 2007, an average of 0.6 VLCADD patients per year were
born, a prevalence of 1:350.000. Since 2007, an average of
3.4 VLCADD patients per year are born, a prevalence of
1:55.000.
The median ages of living pre-NBS patients and living
NBS patients were 23 (range 11-47) and 4 (0-10) years,
respectively, on 1 January 2018. In the pre-NBS group
(n = 27), the diagnosis was made in 23 patients after the
development of symptoms. The remaining four were diag-
nosed by family testing. The median age at diagnosis was
6 (0-38) years. Of the NBS patients (n = 37), one died
before screening could be performed and nine were not
detected by initial NBS. Six out of these nine patients were
later identified by retrospective analysis of bloodspot cards
demonstrating an increased C14:1/C2 ratio, which led to the
adaptation of the Dutch screening for VLCADD.7 This retro-
spective analysis was initiated because of identification of a
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patient missed by NBS. The six patients identified by this
retrospective analysis were all asymptomatic at the time of
their diagnosis, as well as the three affected siblings who
were identified by subsequent family testing. Enzymatic data
were available in 61 patients (24 pre-NBS vs 37 NBS).
Three out of four deceased pre-NBS patients were diagnosed
postmortem.
3.1.2 | VLCAD activity
VLCAD activity was measured in lymphocytes (21 pre-
NBS vs 33 NBS), leukocytes (3 NBS), and/or fibroblasts
(21 pre-NBS vs 29 NBS) (Figure 2A and B). The median
enzyme activity measured in lymphocytes of pre-NBS
patients was 5.4% (95% CI: 4.0-8.3) compared to 12.6%
(95% CI: 10.7-17.7; P < 0.001) of the reference mean in
living NBS patients. Median VLCAD activity in lympho-
cytes of deceased NBS patients was significantly lower
(2.9%; 95% CI: −2.1 to 9.0; P < 0.01) than that of living
NBS patients. VLCAD activity measured in fibroblasts did
not differ significantly between pre-NBS patients and NBS
patients but was significantly lower in deceased NBS
patients than that in the other patients (P < 0.05)
(Figure 2B). There was no significant difference between
the patients diagnosed and missed by NBS and other
patients in any of the cell types.
3.1.3 | LC-FAO flux
LC-FAO flux was measured in fibroblasts of 16 pre-NBS
patients and 28 patients born after VLCADD was included
in NBS. The median LC-FAO flux in pre-NBS patients was
33.2% (95% CI: 22.8-48.3) of mean activity in healthy con-
trol fibroblasts vs 41% (95% CI: 40.8-68.0; P < 0.05) in liv-
ing NBS patients (Figure 2C). Median LC-FAO flux in
deceased NBS patients was significantly lower (5.5%; 95%
CI: −0.9 to 11.9; P < 0.02) than that in living NBS patients.
No significant difference was found between patients missed
and diagnosed by NBS. In the pre-NBS group, four patients
had LC-FAO flux <10%, which is considered a severe
impairment in LC-FAO flux.10 In the NBS group, only two
patients had LC-FAO flux <10%. Forty-one patients had
both LC-FAO flux in fibroblasrs as well as VLCAD activity
in lymphocytes done. The relationship between LC-FAO
flux and VLCAD activity is presented in Figure S1.
3.1.4 | Genotype
Genotype information was available for all patients. Ten
pre-NBS patients were homozygous (five carried missense
mutations, three carried frameshift mutations, and two car-
ried splice-site mutations). Eleven NBS patients were homo-
zygous (nine carried missense mutations, one carried
frameshift mutations, and one carried splice-site mutations).
In both pre-NBS as well as NBS patients, the most often
FIGURE 2 The effect of NBS on biochemical phenotypes. Enzymatic assays performed in lymphocytes and fibroblasts from patients
diagnosed by NBS (NBS patients, black filled circles) and patients born before introduction of NBS (pre-NBS patients, open circles). Error bars
represent the mean ± SD. A, VLCAD activity in lymphocytes. B, VLCAD activity fibroblasts. C, LC-FAO flux in fibroblasts. LC-FAO flux, long-
chain fatty acid oxidation flux; NBS, newborn screening; ns, not significant; pre-NBS, before the addition of VLCADD to NBS; VLCADD, very-
long-chain acyl-CoA dehydrogenase deficiency
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detected mutation was the c.848T>C (p.Val283Ala) muta-
tion (9 out of 54 alleles of pre-NBS patients vs 31 out of
74 alleles of NBS patients). This mutation was only seen in
combination with other mutations in the pre-NBS patients,
whereas seven NBS patients carried this mutation homozy-
gously. Seven out of nine patients missed by NBS were
compound heterozygous (six for two missense mutations,
one for a missense mutation, and a frameshift mutation) and
two were homozygous for the c.848T>C (p.Val283Ala)
mutation. The patient who died before NBS was compound
heterozygous for a missense mutation and a frameshift muta-
tion. Two out of three deceased patients diagnosed by NBS
were homozygous for a missense mutation and a frameshift
mutation, and the third was compound heterozygous for a
missense mutation and a splice-site mutation. An overview
of all observed mutations is presented in Table S2.
3.2 | Outcome-related clinical characteristics
of the VLCADD cohort (March
2010-March 2018)
Sixty patients (23 pre-NBS and 37 NBS) (Figure 1B).
3.2.1 | Hypoglycemia
Hypoglycemic events were reported in 12 of 23 (52%) pre-
NBS patients vs 2 out of 37 (5%) NBS patients
(P < 0.0001) (Figure 3A). This includes one out of four
FIGURE 3 The effect of NBS on clinical outcome. Incidence of hypoglycemia (panel A), cardiac complications (panel B), and myopathy and
rhabdomyolysis (panel C) in patients diagnosed by NBS (NBS patients, n = 37) and patients born before introduction of NBS (pre-NBS patients,
n = 23). Colored bars represent the number of patients with ≥1 event of the symptom mentioned in the graph title. The gray bars represent the
number of patients who had never experienced the symptom mentioned in the graph title. Rhythm disturbances that were reported: asystole, first-
degree atrioventricular block, right bundle branch block, bigeminy, premature atrial contractions (pre-NBS), and intraventricular conduction delay,
atrioventricular nodal reentrant tachycardia (NBS). Myopathy-related symptoms are myoglobulinuria, myalgia, exercise intolerance, muscle
weakness (Medical Research Council grade 4 or less), and/or frequent fatigue. Tables divide patients into a “severe” (LC-FAO flux <10% of healthy
controls) and “mild” (LC-FAO flux >10% of healthy controls) enzymatic phenotype. LC-FAO flux was available for 16 pre-NBS and 28 NBS
patients. 1. LC-FAO flux score unavailable in six pre-NBS patients. 2. LC FAO flux score unavailable in nine NBS patients. CK, creatine kinase; L,
liter; LC-FAO flux, long-chain fatty acid oxidation flux; NBS, newborn screening; ns, not significant; pre-NBS, before the addition of VLCADD to
NBS panel; U, unit; VLCADD, very-long-chain acyl-CoA dehydrogenase deficiency
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deceased pre-NBS patients and two out of three deceased
NBS patients. Median age of first hypoglycemic event was
9 (0-18) and 3.5 (0-7) months, respectively (P < 0.32)
(Figure 4). Five out of 12 (42%) pre-NBS patients who had
at least one hypoglycemic event required special education
in later life. Pre-NBS patients who did not experience hypo-
glycemic events all attained normal educational levels. Of
the two NBS patients who had experienced hypoglycemic
events, one required special educational services and one
died at the age of 7 months.
To assess whether the effect of an early diagnosis by
NBS had equal effect in severely and mildly affected
patients, we divided both cohorts into “severe” and “mild”
enzymatic phenotypes based on the results of the LC-FAO
flux analysis in fibroblasts. LC-FAO flux <10% of healthy
values was considered a severe impairment.10 All patients in
this group were homozygous for mutations predicted to
result in truncation of the protein. An LC-FAO flux >10%
of control values was considered relatively mild. In the pre-
NBS group, LC-FAO flux values were available in 16 of the
23 patients, four of whom were considered severe. Of those
four, three patients had experienced at least one hypoglyce-
mic event, and the remaining patient was diagnosed within
the first week of life because of sibling screening. Of the
pre-NBS patients who were considered mild based on
LC-FAO flux, 7 out of 12 (58%) experienced hypoglycemic
events. Of the 37 NBS patients, LC-FAO flux was available
in 28, and only two (7%) were considered severe. Both
severe patients developed hypoglycemic events in contrast
to none of the mild patients.
3.2.2 | Cardiomyopathy and rhythm
disturbances
Cardiomyopathy was observed in five (22%) pre-NBS
patients during infancy and in four (11%) NBS patients
(P < 0.29) (Figure 3B). Three out of five (60%) pre-NBS
patients with cardiomyopathy during infancy completely
recovered within a year after starting LCT restriction and
MCT supplementation. One experienced a relapse with
hypertrophic cardiomyopathy at the age of 14 years induced
by fasting. The median age of detection of cardiomyopathy
was 0.1 (0-0.3) years for pre-NBS patients and 0.6 (0.2-9;
P < 0.06) years for NBS patients (Figure 4). Rhythm distur-
bances were reported in six (26%) pre-NBS patients and in
two (5%; P < 0.05) NBS patients; all except three pre-NBS
patients had documented cardiomyopathy. Cardiomyopathy
was not observed in any of the mild patients based on
LC-FAO flux. Rhythm disturbances were observed in all
severe patients and two mild pre-NBS patients.
FIGURE 4 Clinical
outcome by age. Data on the
timing of symptoms were
available for 18 pre-NBS and
37 NBS patients. The X-axis
represents the age in years. The
total bar represents the number of
patients who have reached this
age. The colored bars represent
the number of patients with ≥1
event of the symptom mentioned
in the graph title. The gray bars
represent the number of patients
who had never experienced the
symptom mentioned in the graph
title. CK, creatine kinase; L, liter;
NBS, newborn screening; pre-
NBS, before the addition of
VLCADD to NBS panel; U, unit
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3.2.3 | Myopathy and myopathy-related
complications
Fourteen out of 23 (61%) pre-NBS patients and 3 out of
37 (8%; P < 0.0001) NBS patients met the criteria for
myopathy (Figure 3C). The median age of onset of myopa-
thy was 14.5 (6-37) years in pre-NBS patients and 5 (1-9;
P < 0.13) years for the NBS patients (Figure 4). The four
severe pre-NBS patients all met the criteria for myopathy as
well as 8 out of 12 (67%) mild pre-NBS patients. One out of
two severe NBS patients met the criteria for myopathy as
well as one out of 26 mild NBS patients. Rhabdomyolysis
was documented in 11 (48%) pre-NBS patients and 4 (11%;
P < 0.003) NBS patients (Figure 3C). The four severe pre-
NBS patients all experienced rhabdomyolysis events, as did
6 out of 12 (50%) mild pre-NBS patients. Both severe NBS
patients experienced rhabdomyolysis events, as did 2 out of
26 (8%) mild NBS patients. Complications related to myopa-
thy were all significantly more prevalent in pre-NBS patients
than those in NBS patients (Figure S2).
3.2.4 | Treatment
An overview of dietary treatment is given in Table S3.
Details on most patients have been reported previously.9
4 | DISCUSSION
This is the first study that compares genetic, biochemical,
and outcome-related clinical characteristics of a nationwide
cohort of VLCADD patients identified by NBS and patients
identified before the addition of VLCADD to NBS. We
demonstrate several important differences between both
groups in genetic and biochemical characteristics. In addi-
tion, a clear beneficial outcome on some, but not all, of the
clinical characteristics is observed, despite longitudinal
follow-up.
Patients identified by NBS generally have higher levels
of enzyme activity and a higher overall LC-FAO flux in cul-
tured fibroblasts than pre-NBS patients, which suggests that
NBS leads to the identification of milder genetic and bio-
chemical phenotypes in the majority of patients (93%). A
better clinical outcome was shown in patients with an LC-
FAO flux >10% identified by NBS compared to that in
patients identified pre-NBS. This is largely the result of pre-
vention of cerebral damage due to hypoglycemia. However,
NBS did not prevent hypoglycemic events and cardiac com-
plications in patients with an LC-FAO flux <10%, indicating
that current therapeutic options are ineffective in these
patients (Figure 3).6,19 Finally, although myopathy-related
complications in pre-NBS patients are significantly more
prevalent than those in NBS patients, these complications
manifested mostly during adolescence, and as the oldest
patients identified by NBS in the Netherlands are now
10 years of age, we cannot yet assess the impact of NBS on
myopathy.
The benefits of early detection come at the cost of detec-
tion of milder phenotypes or even asymptomatic individuals
with VLCADD. Similar effects have been reported for
almost all disorders introduced in NBS programs, including
medium-chain acyl-CoA dehydrogenase deficiency
(MCADD), another disorder of FAO.20–24 NBS for
MCADD resulted in the identification of two to three times
more newborns with MCADD than was expected from the
estimated disease prevalence before its addition to NBS,
which was largely due to identification of very mild
phenotypes.20,24
This study underlines the importance of functional assays
to follow-up on positive screening results given the poor cor-
relation between acylcarnitine and clinical outcome. The
genotype-phenotype correlation has been investigated previ-
ously with poor clinical outcome in patients with homozy-
gous frameshift mutations or mutations that cause deletion,
in agreement with our cohort.25 The correlation between
protein function and missense mutations had been tested
using expression studies in Escherichia coli and molecular
modeling, including some observed in our cohort.26,27 How-
ever, these assays do not take into account the interaction
with other enzymes involved in lcFAO and many individ-
uals picked up by NBS carry compound heterozygous muta-
tions, limiting the translation of these models to clinical
practice.
The most apparent beneficial effect of NBS on outcome
in VLCADD patients is the prevention of hypoglycemic
events in patients with residual enzyme activity. NBS did
not prevent hypoglycemic events in patients with low resid-
ual enzyme activity, which is consistent with VLCADD
cohorts in the United States and Australia.19,28 Comparison
of cohort data before and after initiation of screening is chal-
lenging due to the difference in duration of follow-up, in our
case 47 vs 11 years and the likelihood of missed pre-NBS
cases. However, if one takes into account that it took
32 years to accumulate seven hypoglycemic events in pre-
NBS patients with some residual enzyme activity, it is
unlikely that after 11 years of screening not a single event
has been reported in the NBS patients. It is also important to
note that it is difficult to take into account the role of envi-
ronmental factors that can induce catabolism which may
have changed over time.
The prevalence of cardiac disease in our study is low,
which is also in line with previous reports.19 The yield of
NBS on cardiac symptoms appears to be minimal, as there
was no difference in prevalence between pre-NBS and NBS
patients. Strikingly, patients with LC-FAO flux >10% did
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not develop cardiac symptoms. Since cardiomyopathy and
arrhythmias are, however, also inducible by catabolic situa-
tions in later life, NBS may have a preventive effect.
Myopathy-related symptoms were observed in almost all
pre-NBS patients and in merely three NBS patients. How-
ever, as the highest prevalence of myopathy in pre-NBS
patients is found during adolescence (Figure 4), a period of
life that has not been reached by Dutch NBS patients, long-
term follow-up is needed to study the impact of NBS on the
frequency of myopathy in VLCADD.
With the rapidly expanding NBS programs worldwide, it
is important to realize that the benefit of NBS is not always
easy to prove and that there is no generally accepted guide-
line on how to monitor outcome and hence fully benefit
from NBS programs.29–31 It is even more complicated to
substantiate the decision to discontinue screening, as was
recently done in New Zealand for carnitine uptake disor-
ders.32 Although most NBS programs use the criteria from
Wilson and Jungner33 and the adaptations from the World
Health Organization34 for inclusion of disorders in the NBS
panel, no clear standardized long-term clinical follow-up
system exists, despite the fact that the adapted criteria clearly
state “the objectives of screening should be defined at the
outset” and “program evaluation should be planned from the
outset”.34 Our study underlines the need for definition and
implementation of such evaluation programs that incorporate
clinically relevant effects and possibly even psychological
outcomes of screening over time. The psychological burden
posed to parents of a child with a FAO disorder, including
those whose child is mildly affected or even asymptomatic,
is immense. Feeding problems and fear of metabolic crisis
are common in this group and have a negative impact on
family life.35 Furthermore, given the rarity of most disorders
international collaboration is crucial before disorders are
implemented, or discontinued from screening programs.
In conclusion, NBS for VLCADD has a clear beneficial
effect on the prevention of hypoglycemic events in patients
with some residual enzyme activity. However, for VLCADD
patients with very low residual enzyme activity, NBS does
not prevent hypoglycemia or cardiac complications. Further-
more, it is too soon to establish the effect of NBS on
myopathy-related complications. Hence, long-term clinical
follow-up studies are needed to evaluate and enhance the
beneficial effect of NBS on VLCADD. These studies should
be implemented as part of NBS programs.
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